藥明康德受邀出席第44屆摩根大通醫療健康大會并在主會場發表演講 | Bilingual News

為全球醫藥及生命科學行業提供全方位、一體化新藥研發和生產服務的能力和技術平臺公司--藥明康德（股票代碼：603259.SH/2359.HK）受邀出席第44屆摩根大通醫療健康大會，并在主會場發表演講。

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industries, has been invited to present at the 44th J.P. Morgan Healthcare Conference.

演講時間 | Presentation Session：

北京時間：2026年1月14日（周三）11:30 PM – 1月15日 (周四) 0:10 AM

Pacific Time:January 14, 2026 (Wednesday) 07:30 AM - 08:10 AM

參與方式 | Participation：

網絡直播（可在會議結束后30天內回放）| Webcast (replay active for up to 30 days):

https://jpmorgan.metameetings.net/events/healthcare26/sessions/317164-wuxi-apptec/webcast?gpu_only=true&kiosk=true

演講材料將在會議結束后上傳至公司官網:

The presentation will be available on the Company's website after the conference:

https://www.wuxiapptec.com/investors

關于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）是全球醫藥及生命科學行業值得信賴的合作伙伴和重要貢獻者，致力于通過提供一體化、端到端的新藥研發和生產服務，推動全球醫藥健康創新。公司在亞洲、歐洲、北美等地均設有運營基地，依托獨特的“CRDMO”業務模式，不斷降低研發門檻，助力客戶提升研發效率，為患者帶來突破性的治療方案。目前，公司的賦能平臺正承載著來自全球30多個國家的約6,000家合作伙伴的研發創新項目，致力于將更多新藥、好藥帶給全球病患，早日實現“讓天下沒有難做的藥，難治的病”的愿景。

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.